000			04105nam a22006497a 4500
008			180315s20182018 xxu||||| |||| 00| 0 eng d
022			_a1068-9265
024			_a10.1245/s10434-018-6369-x [doi]
024			_a10.1245/s10434-018-6369-x [pii]
040			_aOvid MEDLINE(R)
099			_a29484565
245			_aCytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience.
251			_aAnnals of Surgical Oncology. 2018 Feb 26
251			_aAnnals of Surgical Oncology. 25(5):1184-1192, 2018 May.
252			_aAnn Surg Oncol. 2018 Feb 26
252			_aAnn Surg Oncol. 25(5):1184-1192, 2018 May.
253			_aAnnals of surgical oncology
260			_c2018
260			_fFY2018
266			_d2018-04-20
501			_aAvailable online from MWHC library: 1994 - present
520			_aBACKGROUND: The multi-institutional registry in this study evaluated the outcome after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases (PM) from small bowel adenocarcinoma (SBA).
520			_aCONCLUSION: The combined treatment strategy of CRS plus HIPEC achieved prolonged survival for selected patients who had PM from SBA with acceptable morbidity and mortality.
520			_aMETHODS: A multi-institutional data registry including 152 patients with PM from SBA was established. The primary end point was overall survival (OS) after CRS plus HIPEC.
520			_aRESULTS: Between 1989 and 2016, 152 patients from 21 institutions received a treatment of CRS plus HIPEC. The median follow-up period was 20 months (range 1-100 months). Of the 152 patients, 70 (46.1%) were women with a median age of 54 years. The median peritoneal cancer index (PCI) was 10 (mean 12; range 1-33). Completeness of cytoreduction (CCR) 0 or 1 was achieved for 134 patients (88.2%). After CRS and HIPEC, the median OS was 32 months (range 1-100 months), with survival rates of 83.2% at 1 year, 46.4% at 3 years, and 30.8% at 5 years. The median disease-free survival after CCR 0/1 was 14 months (range 1-100 months). The treatment-related mortality rate was 2%, and 29 patients (19.1%) experienced grades 3 or 4 operative complications. The period between detection of PM and CRS plus HIPEC was 6 months or less (P = 0.008), and multivariate analysis identified absence of lymph node metastasis (P = 0.037), well-differentiated tumor (P = 0.028), and PCI of 15 or lower (P = 0.003) as independently associated with improved OS.
546			_aEnglish
650			_a*Adenocarcinoma/th [Therapy]
650			_a*Antineoplastic Combined Chemotherapy Protocols/ad [Administration & Dosage]
650			_a*Cytoreduction Surgical Procedures
650			_a*Hyperthermia, Induced
650			_a*Intestinal Neoplasms/pa [Pathology]
650			_a*Peritoneal Neoplasms/th [Therapy]
650			_aAdenocarcinoma/sc [Secondary]
650			_aAdult
650			_aAged
650			_aCytoreduction Surgical Procedures/ae [Adverse Effects]
650			_aDisease-Free Survival
650			_aFemale
650			_aHumans
650			_aIntestinal Neoplasms/th [Therapy]
650			_aIntestine, Small
650			_aLymphatic Metastasis
650			_aMale
650			_aMiddle Aged
650			_aNeoplasm Grading
650			_aPeritoneal Neoplasms/sc [Secondary]
650			_aPostoperative Complications/et [Etiology]
650			_aRegistries
650			_aSeverity of Illness Index
650			_aSurvival Rate
651			_aWashington Cancer Institute
657			_aJournal Article
700			_aSugarbaker, Paul H
790			_aBaumgartner JM, BIG-RENAPE Group, Cashin P, Ceelen W, de Hingh I, Deraco M, Elias D, Fushita S, Glehen O, Goere D, Katayama K, Kusamura S, Levine EA, Liu Y, Morris DL, Piso P, Pocard M, Quenet F, Spiliotis JD, Sugarbaker PH, Tuech JJ, Yonemura Y
856			_uhttps://dx.doi.org/10.1245/s10434-018-6369-x _zhttps://dx.doi.org/10.1245/s10434-018-6369-x
942			_cART _dArticle
999			_c3218 _d3218